Medtide Inc. reported its interim results for the first half of 2025, with revenue rising to RMB 253.8 million from RMB 197.5 million in the same period a year earlier, representing a 28.5% increase. Gross profit reached RMB 155.0 million, up from RMB 107.4 million, with the gross profit margin increasing to 61.1% from 54.4%. Profit before tax was RMB 115.7 million, compared to RMB 58.5 million in the prior-year period. Net profit for the period rose to RMB 102.0 million from RMB 50.6 million, resulting in a net profit margin of 40.2%, up from 25.6%. The company also reported an adjusted net profit (a non-IFRS measure) of RMB 104.1 million, compared to RMB 90.6 million in the previous period. During the period, Medtide Inc. completed its global offering and became a listed company in June 2025. The company stated that it funded its cash requirements primarily through business operations, capital contributions from shareholders, and the issuance of equity shares. Medtide Inc. remains focused on driving sustainable growth through its integrated CRDMO services for peptides and oligonucleotides and continues to manage liquidity with the objective of optimizing stability and returns for shareholders.